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Background: Despite childhood universal VZV immunization was introduced in 2015, there are no 
data on VZV clade distribution in Spain. 
Objectives: To characterize the varicella-zoster virus strains circulating in Spain between 1997 and 
2016. 
Study Design: In this retrospective study, we determined the VZV clades in 294 patients with different 
pathologies (mainly encephalitis, zoster and varicella) by sequencing three fragments within ORF 22, 
ORF 21 and ORF 50 and, subsequently analyzing 7 relevant SNPs. 
Results: Among these 294 patients, 132(44.9%) patients were infected by clade 1, 42(14.3%) patients 
by clade 3, 19(6.5%) by clade 5, 29(9.9%) by clade VI and 3(1%) by clade 4. Four patients (1.4%) 
were infected by clade 2 vOKA strains, who received one dose of live-attenuated varicella vaccine. 
Putative recombinant clade 1/3 was identified in 6 cases (2.0%). Results obtained from partial 
sequences were assigned to clade 1 or 3 in 56(19%) patients and clade 5 or VI in 3(1.0%) patients. In 
the multivariate analysis, encephalitis was independently associated with clades 1 and 3 and age 
>14y.o. (P=0.035 and P=0.021, respectively). Additionally, Madrid had significant fewer cases of 
encephalitis compared with the rest of regions analyzed (P=0.001). 
Conclusions: Higher prevalence of clades 1 and 3 and their relation with encephalitis and age >14y.o. 
suggest earlier introduction of this clades in Spain. Putative interclade 1 and 3 recombinants are 
circulating in patients with encephalitis, herpes zoster and varicella. Several cases were related to 
vOKA vaccination but vaccine strains do not seem to circulate in the general population. 
1. Background 
 
Varicella-zoster virus (Human herpesvirus 3) is the etiologic agent of chickenpox (varicella) following 
primary infection and shingles (herpes zoster), which results from reactivation of latent virus [1]. In 
Spain, varicella vaccination was recommended in susceptible children between 10 and 14 y.o. since 
2005 [2]. From 2005 to 2011, the incidence of VZV and the rate of hospitalized children decreased 
16% and 64%, respectively [3]. Childhood universal immunization at the age of 15 months was 
introduced in 2015, although some regions initiated this schedule earlier. The attenuated vaccine virus 
consists of heterogeneous Oka strain derived from a parental OKA clinical isolate, and it has been 
commercialized under the names of VarilRix and VariVax. 
Vaccination policies should rely on epidemiological surveillance, including the molecular 
characterization of circulating viruses producing, not only varicella, but also herpes zoster or 
neurological disease, in order to evaluate the impact of vaccine programs on the incidence and the 
pattern of viral circulation. Moreover, since recombination events are frequent in VZV [4], surveillance 
studies are also relevant for evaluating the emergence of new vaccine/wildtype or wildtype/wildtype 
recombinants that can result from increased rates of vaccination or migration, respectively. 
Different genotyping SNP-based methodologies have been published [5, 6]. The CDC located a 447 
bp fragment upstream of the C-terminal coding region of the ORF 22 that was highly polymorphic and 
allowed the identification of four genotypes [7]. Following this initial publication, SNPs from ORF 21 
or ORF 50 were added to those used originally in the ORF 22 genotyping scheme [8, 9]. Using this 
strategy, up to seven stable genotypes were identified (E1, E2, M1, M2, M3, M4 and J) within three 
genogroups (E, M and J). At the international VZV Nomenclature Meeting in 2008, a common 
nomenclature based on phylogenetic clades was agreed upon and seven clades were established: Clade 
I (E1), Clade 2 (J), Clade 3 (E2), Clade 4 (M2); Clade 5 (M1), Clade VI (M4) and Clade VII (M3) [10]. 
 
Clade 1 and 3 are the most prevalent in Western Europe and in areas of the world predominantly settled 
by Europeans, while clade 2 was predominant in Japan and the surrounding countries. Clades 4 and 5 
are mostly prevalent in Asian and African countries [9, 11, 12, 13]. However, more recently several 
groups observed an increased circulation of viruses from clade 5 [14, 15]. 
In Spain, there are no data on VZV clade distribution, except for the 31 patients from Catalonia 
diagnosed with varicella that were included in the study of Loparev et al. [16]. 
2. Objectives 
The aim of this study was to characterize VZV clade distribution using clinical samples from patients 
with different pathologies that were received at the National Center of Microbiology in Spain from 
1997 to 2016.  
3. Study Design 
3.1. Patients and Specimens: Clinical specimens were received at the CNM from 78 hospitals from 
different geographical areas of Spain for virological diagnosis between 1997 and 2016. Clinical 
and demographic data were available and included sex, age, type of infection and whether or not 
it was a vaccine suspected case. Sequences from 7 VZV strains were used as reference control for 
sequence alignment: Strain Dumas, clade 1 (accession number X04370), Strain pOKA, clade 2 
(accession AB097933); Strain HJO, clade 3 (accession number AJ871403); Strain DR, accession 
DQ452050, clade 4; Strain CA123, accession DQ457052, clade 5; Strain Sp4242, clade VI [9]; 
Strain 02-1-40, clade VII [10]. This project was approved by the Ethics Committee of the 
“Instituto de Salud Carlos III” (CEI PI 68_2017-v2). 
3.2. DNA extraction, PCR and sequencing: DNA was extracted using the Virus Pathogen Midi Kit in 
the Qiasymphony robot platform, according to the manufacturer’s instructions (Qiagen). In order 
to increase the number of sequence data, a novel nested PCR was designed to amplify regions of 
 
three different ORFs (ORF 21, ORF 22 and ORF 50), primer sequences are shown in Table 1. The 
first PCR amplification round was performed as previously described [9] and for the second round 
the following conditions were used: a denaturalization step at 95ºC for 5 min, followed by 45 
cycles of 94ºC 30sec, 55ºC, 58ºC for ORF 22 and ORF21/50, respectively for 30 sec and 72ºC 45 
sec, eventually an elongation step at 72ºC for 15 min. All reactions were carried out using the 
Platinum SuperFi DNA Polymerase reaction kit (Invitrogen). PCR products were processed for 
Sanger dideoxy sequencing with BigDye v. 3.1 (Applied Biosystems) in a ABI PRISM 3100 
sequencer (Applied Biosystems, California, USA). 
3.3. DNA sequence analysis, clade determination and characterization of wild-type vs. vaccine VZV 
strain: DNA sequence analysis was carried out using the Lasergene SeqMan software. Aligments 
of raw sequence data were performed against expected amplicons using the Dumas strain as a 
reference sequence (GenBank accession number X04370). Determination of the clades was based 
on the genotyping strategy proposed by Loparev et al. [8] and adapted to the new clade 
nomenclature [10] that consisted of sequencing a fragment of ORF22 containing 4 SNPs and either 
ORF21/50 containing 2 SNPs and 1 SNPs, respectively.The three amplicons and all relevant SNPs 
positions at 37902, 38055, 38081, and 38177 for ORF22, positions 33725 and 33728 for ORF21 
and position 87841 for ORF50 were sequenced and analyzed. Clade 2 VZV strains were further 
investigated to determine whether they were vaccine-related VZV by analyzing the three vaccine-
specific SNPs located in the ORF62 at position 106262, 107136, and 107252 [17]. 
3.4. Statistical analysis: A descriptive analysis of the variables was performed. Categorical variables 
were analyzed by the Chi-square test or Fisher exact test. Multivariate logistic regression model 
was used to evaluate the possible confounding factors of having genogroup E and the development 
of encephalitis. Variables included in the model were those that had significance in the bivariate 
analysis (such as genogroup and region) or those that had clinical relevance (such as age and year 
 
of detection). In all statistical analysis, conditions of application have been checked to be applied 
in each test. Results were analyzed using SPSS version 15.0 software (SPSS, Chicago, IL). 
Association was expressed by odds ratio (OR) and the 95% confidence interval (95% CI). 
Differences were considered statistically significant when P values were below 0.05.  
 
4. Results 
4.1. Study population: Table 2 summarizes baseline characteristics of the patients included in the 
study. Detailed information for each patient regarding age, year of detection, pathology and 
particular SNPs is shown in table 1 of supplementary material. Clinical samples used in this study 
were residual samples available after performing the PCR test for diagnosis. Thus, a total of 294 
VZV PCR-positive clinical samples from 294 patients which yielded sequence DNA data for 
reliable analysis were available for this study. Neurological disease and other related 
complications were overrepresented because the CNM is a national reference laboratory for this 
type of disease. There was no reported epidemiological relationship between patients. The type of 
sample collected was as follows: 164 (55.8%) were CSF, 92 (31.3%) vesicle fluid, 3 (1.0%) 
esophagus biopsy, 2 (0.7%) gastric biopsy, 1 (0.3%) bowel biopsy, 2 (0.7%) cervix brushed, , 4 
(1.4%) humor vitreous, 3 (1.0%) bronco alveolar wash, 2 (0.7%) amniotic fluid, 1 (0.3%) blood 
and 11(3.7%) serum. 
4.2. Sequence analysis: Complete sequences of DNA fragments containing relevant SNPs were 
obtained in 235 (79.9%) of the samples. The remaining 59 (20.1%) samples were partially 
sequenced. The distribution of clades obtained is described in Table 3. In the results from complete 
sequences, clade 1 was the most predominant in 132 (44.9%) of the samples analyzed, followed 
by clade 3 in 42 (14.3%) of the samples. Results obtained from partial sequences were assigned to 
clade 1 or 3 in 56 (19%) samples and clade 5 or VI in 3 (1.0%) samples. All 4 (1.4%) cases of 
clade 2 identified (3 children with herpes zoster and 1 immunocompromised adult patient with 
encephalitis and retinitis) were VZV vaccine related since vOKA specific SNPs located in the 
ORF62 at position 106262, 107136, and 107252 were found. These results confirmed clinical 
suspicion of vaccine-related cases. All 4 cases of clade 2 VZV received only one dose of the VZV 
vaccine, and one of them developed severe neurological disease. In addition, six out of the 235 
 
VZV with complete sequences were identified as putative recombinants between clade 1 and clade 
3. The identified SNPs are as follows: ORF 22: A, T, A, G for positions 37902, 38055, 38081, and 
38177, respectively; ORF 21: C, C for positions 33725 and 33728, respectively; ORF 50: C for 
position 87841. Of the putative interclade recombinants found, 4 were detected from CSF in 
patients with encephalitis, 1 with zoster and 1 with varicella. 
4.3. Analysis of clade distribution: We first analyzed the association between developing a specific 
clinical pathology and having an infection with VZV of different clades (Figure 1). Of the three 
most frequent pathologies, encephalitis tended to be associated more frequently with the clades 1 
(64; 41.8%) and 3 (26; 17%), zoster with clades 1 (45; 50.6%) and 3 (13; 14.6%) and varicella 
with the clade 1 (9; 42.8%), clade 5 (3; 14.3%) and VI (2; 9.5%).We next analyzed the association 
of the clades with a specific pathology and geographical distribution (Table 4.a). A statistically 
significant association was found between clades and pathology, where encephalitis was more 
frequently associated with clades 1 and 3 than clades 4, 5 and VI (56.4% vs 37%; P=0.01). In 
addition, bivariate analysis revealed that clades 4, 5 and VI were significantly more frequent in 
Madrid than in the other regions of Spain studied (22.7% vs 11.8%; P=0.023). In order to find 
significant association between variables, we aggregated the related clades in the former 
genogroups as follows: Genogroup E (clades 1 and 3) and Genogroup M (clades 4, 5 and VI). The 
multivariate analysis of the genogroups revealed a significant association between encephalitis 
with clades 1 and 3 and with age >14 years old ((P=0.035 and P=0.021, respectively); Table 4.b). 
Additionally, significantly fewer cases of encephalitis were found in Madrid compared with all 
other regions studied (P=0.001; Table 4). No associations were found between VZV clades and 
other variables such as gender and year of detection. No significant trend of the VZV clades over 
all study period was found. 
5. Discussion 
 
In the present study, we performed a novel molecular epidemiological study of cases of VZV infection 
in patients in Spain with different pathologies, including neurological disease, varicella and varicella 
zoster, among others. Several studies have demonstrated a regional dominance of specific clades 
established by many factors such as introduction of strains through immigration to naïve populations. 
Geographic distribution of clades is supposed to be faded over time because of increased rates of 
immigration and travel, or by extensive vaccination with live-attenuated clade 2 strains. Eventually, 
most VZV strains will become mosaic genomes, which would make it challenging to define VZV 
clades in the future. Our results confirm that clade 1 and 3 are the most predominant clades in Spain, 
as well as in the European population [15], representing 80.3% of the total VZV cases analyzed. In our 
study, clade VI was found in 9.9% of patient. In the mentioned European study, Spain contributed with 
31 patients with varicella from Catalonia, 23% of which were clade VI [15]. Therefore, it may be 
interesting to investigate if clade VI distribution responds to a regional pattern of recent immigration 
and introduction of clades from other geographical areas, since varicella pathology represents recent 
VZV infection. Significant proportions of clade 1 and 3 cases were obtained from cases of encephalitis 
and herpes zoster that represent earlier infection and, reinforce the idea that clades 1 and 3 emerged 
first as predominant clades in Europe. The fact that most cases of clades 4, 5 and VI were found in the 
area of Madrid supports the hypothesis of the influence of immigration. 
We were unable to assign the clade to six clinical samples, despite the fact that the VZV DNA 
fragments containing the relevant SNPs were fully sequenced. Recent studies have demonstrated that 
at least some of the VZV clades emerged through recombination [4]. Compared with other human 
herpesvirus, the VZV genome has an estimated mutation rate ten times lower than its counterpart 
herpes simplex virus (HSV) and 40 times lower than cytomegalovirus (CMV) [12]. Interestingly, we 
found that these six cases of VZV had the same SNPs combination in ORF 21, 22 and 50 than the 
CII/CSF/2909/2011 strain described by Norberg et al [16]. Therefore, our analysis suggests that these 
 
samples were in fact putative interclade 1 and 3 recombinants. As clade 1 and 3 were found as the most 
common circulating VZV in our study, it is not surprising that these putative recombinants, but no 
others, were detected. The characteristics of the patients and pathologies associated with the six 
putative interclade recombinants found suggest that these strains already circulate in the general 
population. These results do not preclude that other recombinants were present, since the method used 
in this study only analyzes fragments from three ORFs.  
Moreover, other sequencing methods such as the next generation sequencing should be used to detect 
mixed VZV populations in the same sample, since direct sanger sequencing is not sensitive enough to 
detect minor (<20%) viral sub-populations. One study performed in a cohort of adults from Africa and 
Asia that migrated to UK showed a 30% reactivated clade 1 and 3 strains despite a history of varicella 
supposed to be caused by other clades in the country of origin [18]. Furthermore, cases of varicella 
caused by co-infection with two different clades have been previously reported, and indicates the 
potential for recombination, particularly in regions where co-circulation of mixed clades has been 
identified [19]. In this sense, it is postulated that the introduction of the live-attenuated Oka varicella 
vaccine could lead to the recombination of wild-type viruses and hence the need for monitoring and 
characterizing the emerging recombinant VZV strains which could be more virulent. The 4 cases of 
clade 2 found in this study were in fact from patients who received one dose of VZV vaccine and, we 
confirmed that the detected strains were vOKA vaccine strains and unfortunately, one of them 
developed severe neurological disease. However, clade 2 strains have not been found in non-vaccinated 
patients suggesting that vaccine strains do not circulate among the population. 
A limitation of this study is that may not be epidemiologically representative of all cases of VZV 
disease in Spain since we only analyzed those cases that were sent to the CNM, and thus neurological 
diseases were overrepresented. It is also possible that more recombinants could be detected if the 
complete genome was studied. Thus, deep sequencing and phylogenetic studies are needed to detect 
 
other recombinant strains and to assess whether or not all six recombinants have a monophyletic origin 
since these cases were geographically sparse. 
In conclusion, this is the first study that characterizes VZV clade distribution in Spain. Similar to the 
European population, clade 1 and 3 are the most predominant clades in Spain. The results from this 
study also indicate that wild-type recombinant VZV circulates in Spain. Although several cases of 
herpes zoster and one of encephalitis and retinitis are directly related to vaccination, clade 2 vOKA 
strains might potentially circulate in the population. Thus, molecular epidemiological studies for the 
surveillance of circulating varicella-zoster viruses are highly recommended. 
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Table 1. Primers used for nested PCR in ORF 21, 22 and 50. 











































*Dumas strain GenBank accession number X04370. 
  
 


















Gender male, n (%) 148 (59%) 
Age, median (IQR) 55 (30-74) 
Diagnosis, n (%)   
           Colitis 1 (0.3%) 
           Retinitis 3 (1.0%) 
           Esophagitis 5 (1.7%) 
           Encephalitis 153 (52%) 
           Encephalitis and retinitis 1 (0.3%) 
           Encephalitis and Varicella 2 (0.7%) 
           Encephalitis and Herpes Zoster 12 (4.1%) 
           Pneumonia 3 (1.0%) 
           Ramsay-Hunt Syndrome 2 (0.7%) 
          Ramsay-Hunt Syndrome and Encephalitis 2 (0.7%) 
          Varicella 23 (7.8%) 
          Herpes Zoster 87 (29.6%) 
Region, n(%)  
           Madrid 155 (52.7%) 
           Other: 113 (38.4%) 
                     Castilla-León 35 
                     Galicia 16 
                     Castilla-La Mancha 16 
                     Andalucia 14 
                     València 10 
                     Navarra 9 
                     Extremadura 5 
                     Murcia 4 
                     La Rioja 2 
                     Iles Balears 1 
                    Catalunya 1 
            Unknown 26 
Suspected from VZV vaccine, n  4  
Note: Interquartile Range (IQR)  
 






Total            
N=294 
Clade / Genogroup  n (%) 
          1 / E 132 (44.9%) 
          1 or 3 / E 56 (19%) 
           2 / J 4 (1.4%) 
           3 / E 42 (14.3%) 
           4 / M 3 (1%) 
           5 / M 19 (6.5%) 
           5 or VI / M 3 (1.0%) 
           rec 1-3 / E 6 (2.0%) 
           VI / M 29 (9.9%) 
           VII / M  0 (0%) 
 
Table 4. Statistical analysis: a. Bivariate analysis of the association of the clades with a specific 
pathology and geographical distribution (Chi Square test). b. Multivariate analysis of the association 
of the clades with a specific pathology, geographical distribution and age. 
Variable N (%)  Total P 
Clades Pathology   
 
Encephalitis Other pathologies  
 
1 and 3 133 (56.4%) 103 (43.6%) 236 0.01 
4, 5 and VI 20 (37%) 34 (63%) 54  
    
 Region    
   Madrid Other regions   
1 and 3 119 (77.3%) 97 (88.2%)  216  
4, 5 and VI 35 (22.7%) 13 (11.8%) 48 0.023 
     
 
 
Variable OR (CI 95%) P 
Encephalitis 
Clades 1 and 3 2.177 (1.058-4.479) 0.035 
Region (Madrid) 0.379 (0.215-0.667) 0.001 
Year of detection 0.975 (0.910-1.044) 0.460 
Age (>14 years old) 3.605 (1.213-10.709) 0.021 
